Bedaquiline

BreastfeedingPediatric

FDA APPROVAL DATE: 12/28/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Ketoconazole, Rifabutin, Rifampin, Rifapentine, Strong CYP3A4 inducers or inhibitors

PREGNANCY CATEGORY: B

INCREASED RISK OF DEATH / QT PROLONGATION

See full prescribing information for complete boxed warning.

Our database has 34 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of bedaquiline in the Taylor & Francis journal Expert Opinion on Drug Safety.

  (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 01/20/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top